TY - JOUR
T1 - Association of macroeconomic factors with nonrelapse mortality after allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia
T2 - An analysis from the acute leukemia working party of the EBMT
AU - Giebel, Sebastian
AU - Labopin, Myriam
AU - Ibatici, Adalberto
AU - Browne, Paul
AU - Czerw, Tomasz
AU - Socie, Gerard
AU - Unal, Ali
AU - Kyrcz-Krzemien, Slawomira
AU - Bacigalupo, Andrea
AU - Goker, Hakan
AU - Potter, Mike
AU - Furness, Caroline L.
AU - McQuaker, Grant
AU - Beelen, Dietrich
AU - Milpied, Noel
AU - Campos, Antonio
AU - Craddock, Charles
AU - Nagler, Arnon
AU - Mohty, Mohamad
N1 - Publisher Copyright:
© AlphaMed Press 2016.
PY - 2016/2/11
Y1 - 2016/2/11
N2 - Purpose. From a global perspective, the rates of allogeneic hematopoietic cell transplantation (allo HCT) are closely related to the economicstatus of acountry. However, apotential association with out come has not yet been documented. The goal of this study was to evaluate effects of health care expenditure (HCE), Human Development Index (HDI), team density, and center experience on non relapse mortality (NRM) after HLA-matched sibling alloHCT for adults with acute lymphoblastic leukemia (ALL). Patients and Methods. A total of 983 patients treated with myeloablative alloHCT between 2004 and 2008 in 24 European countries were included. Results. In a univariate analysis, the probability of day 100 NRM was increased for countries with lower current HCE (8% vs. 3%; p = .06), countries with lower HDI (8% vs. 3%; p = .02), and centers with less experience (8% vs. 5%; p = .04). In addition, the overall NRM was increased for countries with lower current HCE (21% vs. 17%; p = .09) and HDI (21% vs. 16%; p = .03) and for centers with lower activity (21%vs.16%;p = .07). Inamultivariate analysis, the strongest predictive model forday100NRMincluded currentHCE greater than the median (hazard ratio [HR], 0.39;p = .002).The overall NRM was mostly predicted by HDI greater than the median (HR, 0.65; p = .01). Both lower current HCE and HDI were associated with decreased probability of overall survival. Conclusion. Both macroeconomic factors and the socioeconomic status of a country strongly influence NRM after alloHCT for adults with ALL. Our findings should be considered when clinical studies in the field of alloHCT are interpreted.
AB - Purpose. From a global perspective, the rates of allogeneic hematopoietic cell transplantation (allo HCT) are closely related to the economicstatus of acountry. However, apotential association with out come has not yet been documented. The goal of this study was to evaluate effects of health care expenditure (HCE), Human Development Index (HDI), team density, and center experience on non relapse mortality (NRM) after HLA-matched sibling alloHCT for adults with acute lymphoblastic leukemia (ALL). Patients and Methods. A total of 983 patients treated with myeloablative alloHCT between 2004 and 2008 in 24 European countries were included. Results. In a univariate analysis, the probability of day 100 NRM was increased for countries with lower current HCE (8% vs. 3%; p = .06), countries with lower HDI (8% vs. 3%; p = .02), and centers with less experience (8% vs. 5%; p = .04). In addition, the overall NRM was increased for countries with lower current HCE (21% vs. 17%; p = .09) and HDI (21% vs. 16%; p = .03) and for centers with lower activity (21%vs.16%;p = .07). Inamultivariate analysis, the strongest predictive model forday100NRMincluded currentHCE greater than the median (hazard ratio [HR], 0.39;p = .002).The overall NRM was mostly predicted by HDI greater than the median (HR, 0.65; p = .01). Both lower current HCE and HDI were associated with decreased probability of overall survival. Conclusion. Both macroeconomic factors and the socioeconomic status of a country strongly influence NRM after alloHCT for adults with ALL. Our findings should be considered when clinical studies in the field of alloHCT are interpreted.
KW - Acute lymphoblastic leukemia
KW - Health care expenditure
KW - Hematopoietic cell transplantation
KW - Human development index
KW - Non-relapse mortality
UR - http://www.scopus.com/inward/record.url?scp=84960495183&partnerID=8YFLogxK
U2 - 10.1634/theoncologist.2015-0314
DO - 10.1634/theoncologist.2015-0314
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 26869584
AN - SCOPUS:84960495183
VL - 21
SP - 377
EP - 383
JO - Oncologist
JF - Oncologist
SN - 1083-7159
IS - 3
ER -